A stricter interpretation: the EPO and antibodies
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
COVID-19: Protection of IP for AI tools
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.
Why Santen ends Neurim-style SPCs
In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.
The right recipe for the repurposing omelette
Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue.
How patents for transgenic mice got caught in a sufficiency trap
As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
No SPC crown for Royalty Pharma
An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Could good intentions lead to future danger?
The rush to open access to IP-protected tech, medicines and devices in the fight against COVID-19 could cause problems later, argues MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch.
Five core IP legal principles in life sciences
In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.
Trade secrets: an alternative for life sciences IP?
Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.
EPO’s G3/19: no turning back?
The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.
